Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
Kymera Therapeutics (NASDAQ: KYMR) will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 9:00 a.m. PT / 12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will review Kymera’s clinical progress and anticipated 2026 milestones.
A live webcast of the presentation and Q&A will be available under “News and Events” in the Investors section of the company website at www.kymeratx.com, with a replay and archived presentation available after the event.
Details
News Market Reaction – KYMR
On Jan 6, the day this news came out, KYMR closed 1.45% above the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation date
- January 13, 2026
- J.P. Morgan Healthcare Conference slot
- Presentation time PT
- 9:00 a.m. PT
- Conference presentation
- Presentation time ET
- 12:00 p.m. ET
- Conference presentation
Historical Context
-
Closed upsized public offering with full underwriters’ option exercise.
-
FDA Fast Track designation for KT-621 in atopic dermatitis.
-
Priced upsized public offering of 7,000,000 shares at $86.00.
-
Proposed $500.0M common stock offering with underwriter option.
-
Reported positive BroADen Phase 1b KT-621 data in AD patients.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 13, 2026, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will provide an overview of the Company’s progress and anticipated milestones for 2026.
A live webcast of the presentation and Q&A session will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast and the presentation will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.